Kramkimel N - Search Results

1

Population Pharmacokinetics/Pharmacodynamics of Dabrafenib Plus Trametinib in Patients with BRAF-Mutated Metastatic Melanoma.

Balakirouchenane D, Guégan S, Csajka C, Jouinot A, Heidelberger V, Puszkiel A, Zehou O, Khoudour N, Courlet P, Kramkimel N, Lheure C, Franck N, Huillard O, Arrondeau J, Vidal M, Goldwasser F, Maubec E, Dupin N, Aractingi S, Guidi M, Blanchet B. Balakirouchenane D, et al. Among authors: kramkimel n. Cancers (Basel). 2020 Apr 9;12(4):931. doi: 10.3390/cancers12040931. Cancers (Basel). 2020. PMID: 32283865 Free PMC article.

2

Vemurafenib pharmacokinetics and its correlation with efficacy and safety in outpatients with advanced BRAF-mutated melanoma.

Kramkimel N, Thomas-Schoemann A, Sakji L, Golmard J, Noe G, Regnier-Rosencher E, Chapuis N, Maubec E, Vidal M, Avril M, Goldwasser F, Mortier L, Dupin N, Blanchet B. Kramkimel N, et al. Target Oncol. 2016 Feb;11(1):59-69. doi: 10.1007/s11523-015-0375-8. Target Oncol. 2016. PMID: 26208946

3

Sarcoidosis in Patients Treated with Vemurafenib for Metastatic Melanoma: A Paradoxical Autoimmune Activation.

Lheure C, Kramkimel N, Franck N, Laurent-Roussel S, Carlotti A, Queant A, Goldwasser F, Avril MF, Dupin N. Lheure C, et al. Among authors: kramkimel n. Dermatology. 2015;231(4):378-84. doi: 10.1159/000439400. Epub 2015 Oct 10. Dermatology. 2015. PMID: 26452227

4

Locally Advanced Unresectable Vaginal Melanoma: Response With Anti-Programmed Death Receptor 1.

Chanal J, Kramkimel N, Guegan S, Moguelet P, Fourchotte V, Avril MF. Chanal J, et al. Among authors: kramkimel n. J Low Genit Tract Dis. 2016 Jan;20(1):e4-5. doi: 10.1097/LGT.0000000000000168. J Low Genit Tract Dis. 2016. PMID: 26704337 No abstract available.

5

Pembrolizumab-induced polymyalgia rheumatica in two patients with metastatic melanoma.

Garel B, Kramkimel N, Trouvin AP, Frantz C, Dupin N. Garel B, et al. Among authors: kramkimel n. Joint Bone Spine. 2017 Mar;84(2):233-234. doi: 10.1016/j.jbspin.2016.01.007. Epub 2016 Apr 25. Joint Bone Spine. 2017. PMID: 27133763 No abstract available.

6

Age and clear eyes are associated with an increased risk of cutaneous squamous cell carcinomas in vemurafenib-treated melanoma patients.

Herms F, Kramkimel N, Regnier-Rosencher E, Carlotti A, Chanal J, Boitier F, Aractingi S, Dupin N, Avril MF. Herms F, et al. Among authors: kramkimel n. Melanoma Res. 2016 Oct;26(5):487-91. doi: 10.1097/CMR.0000000000000275. Melanoma Res. 2016. PMID: 27261949

7

Plasma vemurafenib exposure and pre-treatment hepatocyte growth factor level are two factors contributing to the early peripheral lymphocytes depletion in BRAF-mutated melanoma patients.

Puszkiel A, White-Koning M, Dupin N, Kramkimel N, Thomas-Schoemann A, Noé G, Chapuis N, Vidal M, Goldwasser F, Chatelut E, Blanchet B. Puszkiel A, et al. Among authors: kramkimel n. Pharmacol Res. 2016 Nov;113(Pt A):709-718. doi: 10.1016/j.phrs.2016.06.032. Epub 2016 Jul 1. Pharmacol Res. 2016. PMID: 27378568

8

Neutrophilic eccrine hidradenitis in two patients treated with BRAF inhibitors: a new cutaneous adverse event.

Herms F, Franck N, Kramkimel N, Fichel F, Delaval L, Laurent-Roussel S, Carlotti A, Avril MF. Herms F, et al. Among authors: kramkimel n. Br J Dermatol. 2017 Jun;176(6):1645-1648. doi: 10.1111/bjd.15259. Epub 2017 Apr 16. Br J Dermatol. 2017. PMID: 28005274

9

BRAF V600 inhibitor discontinuation after complete response in advanced melanoma: a retrospective analysis of 16 patients.

Vanhaecke C, Deilhes F, Chanal J, Regnier-Rosencher E, Boitier F, Boulinguez S, Avril MF, Guégan S, Dupin N, Aractingi S, Meyer N, Kramkimel N. Vanhaecke C, et al. Among authors: kramkimel n. Br J Dermatol. 2017 Oct;177(4):e94-e95. doi: 10.1111/bjd.15345. Epub 2017 Aug 30. Br J Dermatol. 2017. PMID: 28129668 No abstract available.

10

Sarcopenic overweight is associated with early acute limiting toxicity of anti-PD1 checkpoint inhibitors in melanoma patients.

Heidelberger V, Goldwasser F, Kramkimel N, Jouinot A, Huillard O, Boudou-Rouquette P, Chanal J, Arrondeau J, Franck N, Alexandre J, Blanchet B, Leroy K, Avril MF, Dupin N, Aractingi S. Heidelberger V, et al. Among authors: kramkimel n. Invest New Drugs. 2017 Aug;35(4):436-441. doi: 10.1007/s10637-017-0464-x. Epub 2017 Apr 10. Invest New Drugs. 2017. PMID: 28396974

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

65 results

Search Page